News and Announcements
COMMENTARY
Deformable and degradable nanozymes for inhaled viral pneumonia treatment
Show Less
1
Department of Chemistry, School of Chemistry and Materials, Laboratory of Advanced Materials and Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai,
China
BMT 2025 , 6(1), 103–105;
https://doi.org/10.12336/biomatertransl.2025.01.008
Submitted: 22 January 2025 | Revised: 10 March 2025 | Accepted: 13 March 2025 | Published: 25 March 2025
© 2025 by the Author(s). Licensee Biomaterials Translational, USA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 (CC BY-NC-SA 4.0) (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.en)
Funding
The work was supported by the National Natural Science Foundation of China (22305042, 22475048).
References
- Ruuskanen O, Lahti E, Jennings L, Murdoch D. Viral pneumonia. Lancet. 2011;377:1264-1275. doi: 10.1016/S0140-6736(10)61459-6
- Vigant F, Santos N, Lee B. Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol. 2015;13:426-437. doi: 10.1038/nrmicro3475
- Jiang D, Ni D, Rosenkrans Z, Huang P, Yan X, Cai W. Nanozyme: New horizons for responsive biomedical applications. Chem Soc Rev. 2019;48:3683-3704.
- Wang H, Wan K, Shi X. Recent advances in nanozyme research. Adv Mater. 2019;31:e1805368. doi: 10.1002/adma.201805368
- Peng W, Tai W, Li B, et al. Inhalable nanocatalytic therapeutics for viral pneumonia. Nat Mater. 2024. doi: 10.1038/s41563-024-02041-5
- Bai X, Chen Q, Li F, et al. Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy. Nat Commun. 2024;15:6844. doi: 10.1038/s41467-024-51056-8
- Ye T, Jiao Z, Li X, et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature. 2023;624:630-638. doi: 10.1038/s41586-023-06809-8
- Li J, Wu S, Guo X, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: A randomised, open-label, single-centre trial. Lancet Respir Med. 2022;10:739-748. doi: 10.1016/S2213-2600(22)00087-X
Conflict of interest
The authors declare no conflicts of interest.
